<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36778">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01856621</url>
  </required_header>
  <id_info>
    <org_study_id>3106008 EudraCT 2012-003782-18</org_study_id>
    <nct_id>NCT01856621</nct_id>
  </id_info>
  <brief_title>Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus</brief_title>
  <official_title>Pharmacokinetic Study Comparing Two Salmeterol Fluticasone Propionate Device-metered Dry Powder Inhalers, Salmeterol/Fluticasone Easyhaler and Seretide Diskus 50/500 Mcg/Inhalation; a Randomised, Doubleblind,Single Centre, Single Dose, Crossover Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <authority>Finland: Finnish Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the test product Salmeterol/fluticasone Easyhaler
      with the reference product Seretide Diskus in terms of drug absorbed in the bloodstream.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Pharmacokinetic parameter Cmax of plasma salmeterol concentration</measure>
    <time_frame>Within 34 h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter Cmax of plasma fluticasone propionate concentration</measure>
    <time_frame>Within 34 h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter AUCt of plasma salmeterol concentration</measure>
    <time_frame>Within 34 h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter AUCt of plasma fluticasone propionate concentration</measure>
    <time_frame>Within 34 h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Seretide Diskus and charcoal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seretide Diskus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single-dose of Seretide Diskus (50/500 mcg/inhalation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SF Easyhaler and charcoal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SF Easyhaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide Diskus and charcoal</intervention_name>
    <description>2 inhalations as a single dose</description>
    <arm_group_label>Seretide Diskus and charcoal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Seretide Diskus</intervention_name>
    <description>2 inhalations as a single dose</description>
    <arm_group_label>Seretide Diskus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SF Easyhaler and charcoal</intervention_name>
    <description>2 inhalations as a single dose</description>
    <arm_group_label>SF Easyhaler and charcoal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SF Easyhaler</intervention_name>
    <description>2 inhalations as a single dose</description>
    <arm_group_label>SF Easyhaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females aged 18-60 years

          -  Normal weight, at least 50 kg

        Exclusion Criteria:

          -  Evidence of clinically significant cardiovascular, renal, hepatic, haematological,
             GI, pulmonary, metabolic-endocrine, neurological or psychiatric disease

          -  Any clinically significant abnormal laboratory value or physical finding that may
             interfere with the interpretation of study results or constitute a health risk for
             the subject if he/she takes part in the study

          -  Any condition requiring regular concomitant treatment (including vitamins and herbal
             products) or likely to need any concomitant treatment during the study

          -  Known hypersensitivity to the active substance(s) or the excipient of the drug

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orion Pharma Clinical Pharmacology Unit</name>
      <address>
        <city>Espoo</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 2, 2014</lastchanged_date>
  <firstreceived_date>May 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Charcoal</mesh_term>
    <mesh_term>Salmeterol</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Fluticasone, salmeterol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
